#oncology drugs market

[fairfield-research]

Oncology Drugs Market Growth, Trends, Size, Share, Demand And Top Growing Companies 2031

In a landscape where the battle against cancer rages on, advancements in healthcare systems, public health measures, and novel pharmaceutical therapies have ushered in a new era of hope. According to the National Cancer Institute, the United States saw an estimated 1,806,590 new cancer cases and approximately 606,520 deaths due to the disease in 2020. However, over the past five decades, cancer survival rates have soared from 50% in 1970 to an impressive 70%, thanks to a trifecta of progress.

For more information: https://www.fairfieldmarketresearch.com/report/oncology-drugs-market

Unprecedented Growth Trajectory: The global oncology therapy sales are forecasted to surpass US$ 300 billion by 2026, with oncology contributing 21.7% to total pharmaceutical sales. Fueling this growth are the top 10 pharmaceutical companies, which have declared oncology as their key focus area, driving multibillion-dollar M&A deals and strategic collaborations. Pfizer's acquisition of Array BioPharma for US$11 billion in 2019 and AbbVie's strategic partnership with Genmab for a bispecific antibody development deal worth US$3 billion are testament to this focus.

Diverse Indications Drive Demand: While oncology represents over 20 different indications, a significant portion of revenue stems from just five of them: breast cancer, multiple myeloma, non-small-cell lung carcinoma (NSCLC), prostate cancer, and non-Hodgkin's lymphoma (NHL), which collectively accounted for approximately 65% of the market in 2020. Moreover, with breast, lung, and colorectal cancers expected to collectively account for ~50% of all new cancer diagnoses by 2026, the demand for innovative therapies continues to surge.

Disruptive Trends Reshape Landscape: Innovation in oncology is accelerating, with disruptive technologies such as cell therapy, RNA therapy, viral vectors, and stem cell therapy gaining traction. Recent approvals of CAR-T cell therapies like Kymriah and Yescarta for acute lymphocytic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL) respectively signal a new frontier in cancer treatment. Precision medicine is also driving progress, with over 160 oncology biomarkers approved by 2019, paving the way for more targeted and effective therapies.

Impact of COVID-19: Despite remarkable progress, oncology has been among the worst-hit therapeutic areas amid the COVID-19 pandemic. Decreased demand for physician-administered products, disruptions in cancer screenings, and a decline in new clinical trials have posed significant challenges. However, the industry remains resilient, adapting to the evolving landscape and ensuring continued innovation.

Immuno-Oncology Leads the Way: Immuno-oncology sales are expected to soar to ~US$ 95 billion by 2026, with agents and protein kinase inhibitors comprising ~65% of sales. With over 550 active cell- and gene-therapy agents under clinical development, the future of cancer treatment looks promising. Investments in combination studies and the exploration of new mechanisms underscore the industry's commitment to advancing immuno-oncology therapies.Roche and Keytruda: Leading the Charge: In a highly concentrated market where the top 10 companies capture over 75% of the market value, F. Hoffmann-La Roche AG (Roche) and Merck & Co. stand out as leaders. While Roche maintains its global leadership position, Merck's Keytruda is poised to become the world's top-selling oncology

#oncology drugs market #medicine

[snehahealthcareblogs]

#allied market research #pediatric vaccines market #mhealth market #oncology drugs market #tattoo removal market

[mitalipingale]

https://biiut.com/read-blog/45985_immuno-oncology-drugs-market-analysis-size-share-and-forecast-2031.html

The Immuno Oncology Drugs Market in 2023 is US$ 20.24 billion, and is expected to reach US$ 71.18 billion by 2031 at a CAGR of 17.02%.

#Immuno Oncology Drugs Market #Immuno Oncology Drugs Market Scope #Immuno Oncology Drugs Market Analysis

[poojascmi]

India Immuno-Oncology Drugs Market Is Estimated To Witness High Growth Owing To Increasing Adoption of Immunotherapy

The India Immuno-Oncology Drugs Market is estimated to be valued at US$265 Mn in 2022 and is expected to exhibit a CAGR of 13.1% over the forecast period of 2021-2028, as highlighted in a new report published by Coherent Market Insights. Market Overview: The India Immuno-Oncology Drugs Market refers to the use of immunotherapy drugs for the treatment of various types of cancer. These drugs work by stimulating the body's immune system to recognize and attack cancer cells. The market is driven by the increasing adoption of immunotherapy drugs due to their effectiveness in treating cancer, especially in advanced stages. Immuno-oncology drugs offer advantages such as targeted therapy, reduced side effects compared to traditional chemotherapy, and improved survival rates. The need for these products arises from the growing prevalence of cancer in India and the need for more effective treatment options. Market Key Trends: One key trend in the India Immuno-Oncology Drugs Market is the development of combination therapies. Researchers and pharmaceutical companies are exploring the potential of combining immunotherapy drugs with other treatment modalities, such as chemotherapy or targeted therapy, to enhance their efficacy. For example, the combination of immune checkpoint inhibitors with chemotherapy has shown promising results in clinical trials for various types of cancers. This trend is driven by the need for more effective treatment options and the desire to improve patient outcomes. PEST Analysis: Political: The political factors impacting the India Immuno-Oncology Drugs Market include government regulations and policies related to drug approvals, pricing, and reimbursement. The regulatory framework plays a crucial role in determining the accessibility and affordability of these drugs. Economic: Economic factors influencing the market include healthcare expenditure, insurance coverage, and affordability of immunotherapy drugs. The economic viability of these drugs is an important consideration for patients and healthcare providers. Social: Social factors such as awareness about cancer and its treatment options, patient preferences, and cultural beliefs impact the adoption of immunotherapy drugs. Education campaigns and initiatives to raise awareness about cancer care can drive market growth. Technological: Technological advancements in the field of immuno-oncology, such as the development of novel biomarkers and diagnostic tools, are driving the market. The integration of artificial intelligence and machine learning in cancer research and drug development also presents opportunities for market growth. Key Takeaways: 1: The India Immuno-Oncology Drugs Market Demand is expected to witness high growth, exhibiting a CAGR of 13.1% over the forecast period. This growth is attributed to increasing adoption of immunotherapy in cancer treatment, driven by its effectiveness and advantages over traditional chemotherapy. 2: The fastest growing and dominating region in the India Immuno-Oncology Drugs Market is India due to the high prevalence of cancer and improving healthcare infrastructure. The country has a large patient population seeking advanced treatment options. 3: Key players operating in the India Immuno-Oncology Drugs Market include Amgen Inc., AstraZeneca Plc, Bristol-Myers Squibb, Celgene Corporation, Eli Lilly and Company, Merck & Co., F. Hoffmann-La Roche AG, Johnson & Johnson, Novartis International AG, and AbbVie Inc. These companies invest heavily in research and development to bring innovative immunotherapy drugs to the market. In conclusion, the India Immuno-Oncology Drugs Market is poised to experience significant growth due to the increasing adoption of immunotherapy for cancer treatment. The development of combination therapies, along with favorable political, economic, social, and technological factors, further contribute to market expansion. Key players play a crucial role in driving innovation and bringing advanced therapies to cancer patients in India and globally.

#Immuno-Oncology Drugs Market #Immuno-Oncology Drugs Market Demand #Immuno-Oncology Drugs Market Insights #Immuno-Oncology Drugs Market Outlook #Immuno-Oncology Drugs Market Value #Immuno-Oncology Drugs Market Share #Immuno-Oncology Drugs Market Forecast #chemotherapy #antibodies #personalized medicine #cancer treatments #Cancer

[kajalfw]

https://blacksocially.com/read-blog/147693_global-oncology-cytotoxic-drug-market-size-overview-key-players-and-forecast-202.html

#Oncology Cytotoxic Drug Market Scope #Oncology Cytotoxic Drug Market Share #Oncology Cytotoxic Drug Market Analysis

[insights10]

Insights10 report provides an depth analysis of the Abu Dhabi oncology drugs market. The Abu Dhabi oncology drugs market in 2020 was $244.9 Mn and is expected to increase at a CAGR of 10% reaching $635.2 Mn in 2030 The UAE oncology drugs market size was valued at $579.2 Mn in 2020 and is projected to reach $1,502.3 Mn by 2030

#Cancer #Insights10 #drugs #abu-dhabi #oncology #market analysis

[jesse-pinkman123]

The Oncology Drugs Market disquisition report is an intelligence report that includes precise and precious data on request size, development countries, request share, and profit vaticinations through 2028. It also provides information on the request’s development and capabilities.

#Oncology Drugs Market Outlook #Oncology Drugs Market Growth

[healthcaremreports]

#Immuno-Oncology Drugs Market

[ophthalmotropy]

what's happening in argentina?

I don't fault you for the broad question because I'd ask too, but I need you to know that as a non-smoker I've never felt so strongly the need for a cigarette as I did just now thinking about answering this question. But I'll do my best.

In November of last year, the country elected Javier Milei as president. He would swear into office the next month. Javier Milei is a self-identified anarcho-capitalist and libertarian, although he states he is a minarchist in the short term (meaning he thinks the only functions the State should serve are those of law enforcement: no public education, social development, market regulations, etc etc). Some of his most controversial campaign statements included projects to legalise the free and unregulated sale of organs, and, along with his vice-president Victoria Villarruel (who in her youth organised visits to Jorge Rafael Videla in prison), apologia for the 1976 military dictatorship by revindicating the theory of the two demons (fair warning that from what I skimmed that article is biased in favour of the theory) and casting into doubt the estimated 30.000 victims of state terrorism (torture, disappearance followed by death) (also warning that that article uses the name the military junta gave this process) during its duration.

Since he took over six months ago, the population's purchasing power has dropped by 38%, plunging millions of people below the line of poverty. In stark contrast to this, Milei has been travelling around the world using public funds to visit his ultraright idols; most notably, Trump, who is not the political leader of any country at the moment (making his trip to see him a personal visit and not a diplomatic one, thus invalidating his arguments for using our money to go there).

On the subject of diplomacy, his government has been swinging quite a lot of bats at hornets' nests, accusing China and Brazil of communism and insulting the wife of the president of Spain. All of this is an international relations nightmare that will take endless apologies to undo.

Another interesting resolution deregulates the operations of foreign companies, SPVs, and offshore companies (article in Spanish), with the stated goal of attracting investments. Those types of companies have historically been used to conceal illicit activity, so resolutions in that vein pave the way to effectively turn Argentina into a fiscal paradise. This isn't the only problem they pose (offshore companies don't pay taxes, so there'd be a loss in the public sector, for example), but it is the most worrying to me because they also eliminated restrictions for Sociedades de Acciones Simplificadas (simplified stock companies), most of which have historically been used to commit crimes among which is the drug trade. Once you have narcos in your country, there's no taking it back--Argentina would be at real risk of ceasing to exist as we know it.

This administration is also slashing public spending, resulting in some universities suspending their activities temporarily. They also failed to deliver oncological medicine, depriving cancer patients of assistance the state is obligated to provide. As a result of this, several people have died already. In this climate of extreme poverty, soup kitchens have been shutting down en masse due to the withdrawal of state funding, and laws that protected tenants' rights and regulated rent prices have been severely modified to the detriment of the tenants.

The violent decrease in public spending also resulted in thousands of state workers being fired overnight. The attack is especially centred on state organisations that promote the arts or whose purpose is to fight discrimination. On this subject, 10% of the transgender and travesti workers who had their positions guaranteed by the law were fired illegally, and government members are outspoken about their opposition to this law--which isn't surprising. Diana Mondino, the current chancellor, has compared same-sex marriage to "the right to having lice" while she held a position in Congress. Ricardo Bussi, a current legislator, compared homosexuality to disability in October 2023. Coming to this year, Francisco Sánchez, the Secretary of Religion, said that the laws protecting the right to abortions, divorce, and same-sex marriage "seek to pervert our children and damage society". Milei is also on record describing abortion as "homicide aggravated by the bond".

Also recently, Milei's biographer, Nicolás Márquez, gave a one-hour interview in which he characterised homosexuality as a disease, claiming that when the State "promotes homosexuality" (as it allegedly did before Milei came to power), it is aiding a "self-destructive" conduct, supporting these claims with unfounded statistics about the correlation between STIs and homosexuality; he also denied the existence of homophobia and described lesbians and gays as being "against nature". For the sake of full disclosure, I will say he explicitly freed Milei and his government of responsibility for his declarations--but I think it's really important to point out the kind of people and rhetorics this government is giving a platform to; after all, nobody knew Nicolás Márquez before he started writing for Milei. In approximately the same time frame, and in response to a horrific hate crime that resulted in the death of three lesbians, Manuel Adorni, the presidential spokesman, said that he "doesn't like" to talk about a hate crime because men suffer violence too--and he said this in a press conference.

I'm probably forgetting something important--so much has happened in the past months--but I hope this is enough to give you an impression of the changes our society is undergoing. Please let me know if you have follow-up questions. <3

#answered ask #anonymous #l33chsp34k #argentina

[brightlotusmoon]

This expedited pathway is intended for drugs designed to treat serious conditions such as cancers or neurodegenerative disease. “In oncology care, the FDA standard for approval is often less rigorous in terms of the amount of evidence that’s required because they’re trying to get products to market more quickly since the disease is so serious,” says Joseph Ross, MD, professor of medicine (general medicine) and of public health (health policy and management). “But what you end up with are fairly small trials testing drugs focused on endpoints, such as whether a tumor shrinks, as opposed to whether the patient actually feels better or lives longer.”

After they are approved, the FDA requires confirmatory trials that prove clinical benefit. And if these trials find the drug to be ineffective, they are supposed to be withdrawn from the market. However, too often, says Ramachandran, this does not happen.

Sometimes this is because there is no other drug available. “There’s a concern that clinicians won’t have anything to give to these patients,” Ramachandran explains. But even in instances of what Ramachandran calls “a slam dunk,” where confirmatory trials irrefutably find no benefit, the FDA has historically had a difficult time removing the drugs from the market. Up until last year, its process for drug withdrawal was long and arduous (recently passed legislation streamlines this process). And drug manufacturers frequently refused to withdraw the drugs voluntarily.

-

[snehahealthcareblogs]

#allied market research #oncology #cancer drugs #drugs #cancer

[mitalipingale]

The Immuno Oncology Drugs Market in 2023 is US$ 20.24 billion, and is expected to reach US$ 71.18 billion by 2031 at a CAGR of 17.02%.

#Immuno Oncology Drugs Market #Immuno Oncology Drugs Market Research #Immuno Oncology Drugs Market Report

[poojascmi]

Global Immuno-oncology Drugs Market Is Estimated To Witness High Growth Owing To Increasing Incidence of Cancer and Growing Adoption of Immune Checkpoint Inhibitors

The global Immuno-oncology Drugs Market is estimated to be valued at US$ 17,394.2 million in 2023 and is expected to exhibit a CAGR of 16.8% over the forecast period 2023-2030.

A) Market Overview:

The Immuno-oncology Drugs Market includes various drugs and therapies that utilize the body's immune system to fight cancer. These drugs work by enhancing the immune response against cancer cells, thereby improving the survival rates and quality of life for patients. Key products in the market include immune checkpoint inhibitors, immune modulators, monoclonal antibodies, and cancer vaccines. These treatments have shown promising results in treating various types of cancer, such as lung cancer, melanoma, and bladder cancer.

B) Market Dynamics:

The market is driven by two key factors: the increasing incidence of cancer and the growing adoption of immune checkpoint inhibitors. The incidence of cancer is rising globally, with lung cancer, colorectal cancer, and breast cancer being the most common types. This has led to a significant demand for effective and targeted treatments like Immuno-oncology Drugs.

Additionally, the growing adoption of immune checkpoint inhibitors, such as PD-1/PD-L1 inhibitors and CTLA-4 inhibitors, has revolutionized cancer treatment. These drugs have shown remarkable efficacy in treating multiple types of cancer and have become a standard of care in many cases. For example, drugs like Keytruda and Opdivo have received approvals for multiple indications, including lung cancer and melanoma.

C) Market Key Trends:

One key trend in the Immuno-oncology Drugs Market is the increasing focus on combination therapies. Researchers and pharmaceutical companies are exploring the benefits of combining Immuno-oncology Drugs with other treatment modalities, such as chemotherapy, radiation therapy, and targeted therapy. Combination therapies have shown improved response rates and survival outcomes compared to single-agent therapies. For instance, the combination of Keytruda and chemotherapy has shown superior results in the treatment of lung cancer.

D) SWOT Analysis:

Strengths:

1. Increasing incidence of cancer.

2. Growing adoption of immune checkpoint inhibitors.

Weaknesses:

1. High cost of Immuno-oncology Drugs.

2. Limited patient access and affordability in developing countries.

Opportunities:

1. Advances in personalized medicine and biomarker-driven therapies.

2. Potential for expanding applications of Immuno-oncology Drugs in various cancer types.

Threats:

1. Stringent regulatory pathways for drug approvals.

2. Competition from alternative treatment modalities, such as targeted therapies.

E) Key Takeaways:

- The global Immuno-oncology Drugs Market is expected to witness high growth, exhibiting a CAGR of 16.8% over the forecast period, due to increasing incidence of cancer and growing adoption of immune checkpoint inhibitors.

- North America is expected to dominate the market, owing to the presence of key players, well-established healthcare infrastructure, and high healthcare expenditure.

- Key players operating in the global Immuno-oncology Drugs Market include AbbVie Inc., AstraZeneca, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., and Novartis AG. These companies are investing in research and development, strategic collaborations, and product launches to maintain their market position.

In conclusion, the Immuno-oncology Drugs Market is poised for significant growth due to the increasing incidence of cancer and the adoption of innovative treatments like immune checkpoint inhibitors. Combination therapies and advances in personalized medicine present further opportunities for market expansion. However, challenges such as high costs and limited access in developing countries need to be addressed to ensure equitable patient care.

#Immuno-oncology Drugs Market #Immuno-oncology Drugs Market Study #Immuno-oncology Drugs Market growth #Immuno-oncology Drugs Market Analysis #Immuno-oncology Drugs Market Value #Immuno-oncology Drugs Market insights #Coherent Market Insights #Immuno-oncology Drugs

[kajalfw]

#Oncology Cytotoxic Drug Market Scope #Oncology Cytotoxic Drug Market Share #Oncology Cytotoxic Drug Market Analysis

[reasoningdaily]

‘We’re hemorrhaging money’: US health clinics try to stay open after unprecedented cyberattack

For more than two weeks, a cyberattack has disrupted business at health care providers across the United States, forcing small clinics to scramble to stay in business and exposing the fragility of the billing system that underpins American health care.

“We’re hemorrhaging money,” said Catherine Reinheimer, practice manager at the Foot and Ankle Specialty Center in the suburbs of Philadelphia. “This will probably be the last week that we can keep everybody on full-time without having to do something,” she told CNN. The center is considering taking out a loan to keep the lights on.

The cyberattack disrupted the computer networks of Change Healthcare, which serves thousands of hospitals, insurers and pharmacies nationwide. It prevented some insurance payments on prescription drugs from processing, leaving many care providers footing the bill up front and hoping to get reimbursed.

Change Healthcare, part of UnitedHealth, is one of handful of companies that make up the central nervous system of the US health care market. Its services allow doctors to look up patients’ insurance, pharmacies to process prescriptions, and health clinics to submit claims so they can get paid.

Health care groups have pleaded with the Department of Health and Human Services (HHS) to offer medical practices a financial lifeline. The department on Tuesday said it was taking extraordinary steps to help get claims processed, but some care providers say it’s not nearly enough.

Mel Davies, chief financial officer of Oregon Oncology Specialists, told CNN she is worried that the private clinic that treats 16,000 cancer patients annually could be forced to close if she doesn’t get financial relief soon.

Cash flow has dropped by 50% in the two weeks since the cyberattack, she said. “The magnitude of this is off the charts for us.”

On Thursday night, half a month since the saga began, Change Healthcare announced plans to have its electronic payment platform back online by March 15 and its network for submitting claims restored the following week.

But the financial wreckage caused by the cyberattack will take a lot longer to clean up, health providers and analysts say.

“The prospect of a month or more without a restored Change Healthcare claims system emphasizes the critical need for economic assistance to physicians, including advancing funds to financially stressed medical practices,” Jesse Ehrenfeld, president of the American Medical Association, said in a statement Friday.

Reinheimer, who works at the foot treatment center, said Change Healthcare’s plan to bringing systems back online was a “light at the end of the tunnel … However, it doesn’t solve the immediate issue, which is lack of money today, tomorrow and next week.”

The chaos caused by the cyberattack is prompting a reckoning for senior US cybersecurity officials about the vulnerabilities in hugely important companies that underpin the health care system.

The Change Healthcare hack “is an evolution beyond” other ransomware attacks on individual hospitals “that shows the entire system is a house of cards,” a senior US cybersecurity official told CNN.

Health care executives have been sounding the alarm for several days that the cyberattack is causing severe financial strain on the sector.

The Medical Group Management Association, which represents 15,000 medical practices, has warned of the “devastating” financial fallout from the hack and of “significant cash flow problems” facing doctors. The ransomware attack has “had a severe ongoing impact on cancer practices and their patients,” the nonprofit Community Oncology Alliance said this week.

A week ago, Change Healthcare announced plans for a temporary loan program to get money flowing to health care providers affected by the outage.

But Richard Pollack, head of the American Hospital Association representing thousands of hospitals nationwide, slammed the proposal as “not even a Band-Aid on the payment problems.”

The cyberattack could end up costing Change Healthcare billions of dollars in lost revenue and clients, said Carter Groome, chief executive of cybersecurity firm First Health Advisory.

“This is a huge, huge moneymaker being essentially the middleman or the intermediary between the insurance companies,” Groome told CNN.

Change Healthcare has blamed the hack on a multinational ransomware gang called ALPHV or BlackCat that the Justice Department says has been responsible for ransomware attacks on victims around the world.

A hacker affiliated with ALPHV this week claimed that the company had paid a $22 million ransom to try to recover data stolen in the hack. Tyler Mason, a spokesperson for Change Healthcare, declined to comment when asked if the company had paid off the hackers.

Private experts who track cryptocurrency payments said the hacking group had received a $22 million payment, but it was unclear who made the payment. “A cryptocurrency account associated with ALPHV received a $22 million payment [on March 1],” Ari Redbord, global head of policy at blockchain-tracing firm TRM Labs, told CNN.

For Joshua Corman, a cybersecurity expert who has focused on the health sector for years, the Change Healthcare cyberattack is clear evidence that the US health sector is not as resilient as it needs to be in a crisis.

Acquisitions that have merged multibillion-dollar healthcare companies have accentuated the problem so that “a single point of failure can have outsized, cascading reach and consequences,” said Corman, who helped lead a federal taskforce to protect coronavirus research from hacking.

If federal officials “don’t identify the systemically important entities proactively, our adversaries will continue to do it for us … while we burn,” he told CNN.

#us medical crisis #cyber crime #cyber security #We’re hemorrhaging money’: US health clinics try to stay open after unprecedented cyberattack

[sanskruti01]

Generative AI in Healthcare Market to Grow at an 35.1% CAGR Till 2032!

The global Generative AI in Healthcare Market worth USD 1.07 billion in 2023 is likely to be USD 21.74 billion by 2032, growing at a 35.1% CAGR between 2023 and 2032.

According to the stats published by World Health Organization (WHO), approximately 1.28 million adults (between 30 and 79 years of age) have hypertension. Of these, as little as 42% of adults are diagnosed and treated correctly and the remaining population is unaware of this condition. The majority of this population resides in low to middle-income countries of the world. Despite this substantial number of untreated cases, the rising awareness among doctors and the general population regarding health illnesses associated with hypertension is expected to drive the demand for the required devices.

Download White Paper@ https://www.towardshealthcare.com/personalized-scope/5069

A recent report provides crucial insights along with application based and forecast information in the Global Generative AI in Healthcare Market. The report provides a comprehensive analysis of key factors that are expected to drive the growth of this Market. This study also provides a detailed overview of the opportunities along with the current trends observed in the Generative AI in Healthcare Market.

A quantitative analysis of the industry is compiled for a period of 10 years in order to assist players to grow in the Market. Insights on specific revenue figures generated are also given in the report, along with projected revenue at the end of the forecast period.

Report Objectives

To define, describe, and forecast the global Generative AI in Healthcare Market based on product, and region

To provide detailed information regarding the major factors influencing the growth of the Market (drivers, opportunities, and industry-specific challenges)

To strategically analyze microMarkets1 with respect to individual growth trends, future prospects, and contributions to the total Market

To analyze opportunities in the Market for stakeholders and provide details of the competitive landscape for Market leaders

To forecast the size of Market segments with respect to four main regions—North America, Europe, Asia Pacific and the Rest of the World (RoW)2

To strategically profile key players and comprehensively analyze their product portfolios, Market shares, and core competencies3

To track and analyze competitive developments such as acquisitions, expansions, new product launches, and partnerships in the Generative AI in Healthcare Market

Companies and Manufacturers Covered

The study covers key players operating in the Market along with prime schemes and strategies implemented by each player to hold high positions in the industry. Such a tough vendor landscape provides a competitive outlook of the industry, consequently existing as a key insight. These insights were thoroughly analysed and prime business strategies and products that offer high revenue generation capacities were identified. Key players of the global Generative AI in Healthcare Market are included as given below:

Generative AI in Healthcare Market Key Players:

Syntegra

NioyaTech

Saxon

IBM Watson

Microsoft Corporation

Google LLC

Tencent Holdings Ltd.

Neuralink Corporation

OpenAI

Oracle

Market Segments :

By Application

Clinical

Cardiovascular

Dermatology

Infectious Disease

Oncology

Others

System

Disease Diagnosis

Telemedicine

Electronic Health Records

Drug Interaction

By Function

AI-Assisted Robotic Surgery

Virtual Nursing Assistants

Aid Clinical Judgment/Diagnosis

Workflow & Administrative Tasks

Image Analysis

By End User

Hospitals & Clinics

Clinical Research

Healthcare Organizations

Diagnostic Centers

Others

By Geography

North America

Europe

Asia-Pacific

Latin America

Middle East and Africa

Contact US -

Towards Healthcare

Web: https://www.towardshealthcare.com/

You can place an order or ask any questions, please feel free to contact at 

Email:  [email protected]

About Us

We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.

#seo marketing #seo #market analysis #market share #marketing #ai #artificial intelligence #Generative AI #healthcare